Clinical trials: Atrial Functional
Atrial Fibrillation
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
- Trial name
- ARISTA (NCT03839355)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Migraine With Aura, Patent Foramen Ovale
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
The purpose of the study is to compare the rate of comorbidities associated with migraine aura (MA) between persons who have a large circulatory right-to-left shunt (RLS) and those who do not have RLS.
- Trial name
- CAMP (NCT01257880)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Swedish Medical Center
Atrial Fibrillation, Heart Failure
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
- Trial name
- RAD HF (NCT01887353)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Intermountain Health Care, Inc.
Congestive Heart Failure, Left Ventricular Failure
Catheter Ablation vs. Medical Therapy in Congested Hearts With AF
This study is a multi-center, randomized, unblinded, clinical trial. The objective is to determine if catheter-based atrial fibrillation (AF) ablation is superior to medical treatment in patients with impaired left ventricular…
- Conditions
- Congestive Heart Failure, Left Ventricular Failure, Atrial Fibrillation
- Trial name
- CATCH-AF (NCT02686749)
- Testing
- Catheter Ablation, FDA approved anti arrhythmic drug
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- The Cleveland Clinic
Healthy, Atrial Fibrillation
Validation of the Performance of the Electrocardiogram (ECG) Function in the Masimo INVSENSOR00057
The objective of this study is to validate the performance of the electrocardiogram (ECG) function of the Masimo INVSENSOR00057 against contemporaneous measurements
- Trial name
- NCT06071754
- Testing
- Masimo INVSENSOR00057
- Where
- 4 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Left Ventricular Dysfunction
PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
This study will be done in patients who require the implantation of a cardiac pacemaker (an electronic device that controls the heartbeat) for complete heart block (a heart rhythm abnormality resulting in a slow heart beat).
- Trial name
- PROTECT-PACE (NCT00461734)
- Testing
- RV lead placement site
- Where
- 18 sites in Australia, New Zealand and 1 more
- Volunteers
- 248 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Fluid Overload, Fluid Loss
Atrial Natriuretic Peptide in Assessing Fluid Status
Biomarkers can play a significant role in fluid status assessment intraoperatively.
- Conditions
- Fluid Overload, Fluid Loss, Volume Overload, Cardiac Disease
- Trial name
- NCT05070819
- Testing
- pro-ANP
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Atrial Fibrillation
Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation
The objective of the study was to estimate the efficacy of telmisartan and amlodipine combination on the restoration of left atrial mechanical function after atrial fibrillation catheter ablation.
- Trial name
- NCT02734355
- Testing
- Telmisartan 80 mg and amlodipine 5 mg
- Volunteers
- 64 people
- Sponsor
- Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Atrial Fibrillation
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
The goal of this study is to assess dabigatran pharmacokinetics in NVAF subjects with severe renal impairment defined as creatinine clearance between 15 and 30 mL/min calculated by Cockcroft-Gault formula.
- Trial name
- NCT01896297
- Testing
- Pradaxa, dabigatran etexilate
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Effect of Balloon Cryoablation on Left Atrial Function
Atrial fibrillation is a common and disabling irregular heart rhythm, that affects 1 to 1.5 million Americans. Recent clinical experience with the Medtronic Arctic Front™ Cardiac CryoAblation Catheter System suggests that it can…
- Trial name
- CRYO-LA (NCT00821015)
- Testing
- Pulmonary vein isolation with cryoballoon catheter
- Volunteers
- 27 people
- Sponsor
- Vivek Reddy
Permanent Atrial Fibrillation
Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Atrial fibrillation is a common heart rhythm disturbance, causing important discomfort for patients, a high risk of stroke, frequent hospital admissions and a two-fold increase in death.
- Trial name
- RATE-AF (NCT02391337)
- Testing
- Bisoprolol, Digoxin
- Where
- 2 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- University of Birmingham
Left Atrial Appendage Closure, WATCHMAN Device Implantation
The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial
This study will evaluate thrombogenicity in patients undergoing left atrial appendage closure using the WATCHMAN device. Parameters of thrombosis and platelet function, as well as other bio-markers, will be measure before…
- Trial name
- NCT03040622
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Inova Health Care Services
Atrial Fibrillation
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement
Primary Objective: Evaluate the effect of dronedarone versus placebo (standard therapy) in slowing the progression of adverse left atrial remodeling in patients with atrial fibrillation (AF) following 12 months of treatment.
- Trial name
- ODYSSEUS (NCT01198873)
- Testing
- Dronedarone
- Where
- 57 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Sanofi
Acute Myocardial Infarction
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction
This purpose of this study is to examine the relationship between HMGB-1 and postinfarction predictors of outcome such as cardiopulmonary and echocardiographic parameters before and after a 6-month exercise-based cardiac…
- Trial name
- NCT00755131
- Testing
- Exercise-based Cardiac Rehabilitation program
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Federico II University